However, among the glycemia-lowering agents used in diabetes care, liraglutide 3 mg (a GLP-1 receptor agonist) is the most clearly indicated for weight loss (Garber 2020)
BACFO Pharmaceutical has given the manufacturing of this product to improve healthy skin and reduce skin-related problems
A grey-market vial might save you a hundred dollars compared to a compounding pharmacy

Patients who do best with pens (Zepbound): Insurance covers Zepbound with a copay under $50 per month Qualify for Eli Lilly savings card (commercially insured, not Medicare/Medicaid) Tolerate the standard titration schedule without significant side effects Prefer not to handle syringes or draw medication Have dexterity or vision issues that make syringe use difficult Are comfortable with the environmental waste trade-off Patients who do best with vials (compounded tirzepatide): Pay out-of-pocket (no insurance coverage or high deductible) Need customized titration (slower escalation, non-standard doses, or dose reductions) Have a history of GI side effects on GLP-1 medications and want flexible dosing Prefer lower cost and are comfortable with a 90-second injection process Value reduced medical waste Are willing to use a compounded (non-FDA-approved) product The hybrid pattern: Some patients start with pens during the first 2-3 months of titration (when insurance coverage and savings cards apply), then switch to compounded vials for long-term maintenance once they reach a stable dose and the savings card expires

We chatted about a bunch of things, including the issue of weight loss drug ads running during womens sports events and why its even more insidious than it might appear at first glance
- A nationally representative survey of 2,000 Americans found that a majority, across political lines, support greater regulation of ultra-processed foods